( SAN DIEGO California 23 May 2007 - Th...)In New Study, Duloxetine Was Equally Effective, Regardless of,Switch Method, in Reducing Painful Symptoms in Ssri Non- or,Partial-responders with Depression,Health

SAN DIEGO, California, 23 May 2007 - The antidepressant duloxetine hydrochloride was equally effective in reducing painful symptoms in depressed patients who did not respond, or responded only partially, to treatment with a selective serotonin reuptake inhibitor (SSRI), regardless of whether those patients were switched from an SSRI abruptly or gradually.¹ This new data was presented today at the American Psychiatric Association’s 160^th Annual Meeting in San Diego, Calif.

Between 30-50 percent of individuals treated with a given antidepressant do not respond to that treatment.^2,3 As a result, physicians often need to switch patients from one antidepressant to another. Although this is a common clinical scenario, there are relatively few published studies to guide physicians on how to switch patients from one antidepressant to another.

“Recent data suggests the more antidepressants an individual has tried, the less likely they are to benefit from a new antidepressant.⁴ Therefore it is important to maximise the chance of remission earlier in the treatment pathway,” said Prof. Angel L. Montejo, Psychiatry Research Coordinator, University Hospital of Salamanca, Spain. “These results demonstrate that a switch to duloxetine results in a significant decrease in the painful symptoms in patients with depression and was well tolerated regardless of the switch method used.”

The new results are based on several secondary endpoints from a study comparing the efficacy, safety and tolerability of two switch methods in 368 patients who remained depressed despite taking an SSRI for at least six weeks.⁵ Participants were randomized to either abrupt discontinuation of their SSRI (the Direct Switch, or DS group) or to a gradual/tapered discontinuation of their SSRI (the Start-Taper Switch, or STS group). Both groups began taking duloxetine 60 mg/day at the beginni
'"/>




Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. In New Study, Duloxetine Reduced Non-specific Pain and Emotional Symptoms Associated with Depression
2. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
3. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
4. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
7. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
8. The International Myeloma Foundation Says New Clinical Trial Results Could Improve Survival While Reducing Side Effects For Many Patients
9. New Study Confirms Role for Pertussis Immunization of Entire Family in Reducing Infant Pertussis
10. Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in Their Phase 2 Clinical Trial
11. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo